Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial
07:06am, Monday, 27'th Apr 2026
Intellia Therapeutics said on Monday its experimental therapy for a rare genetic disorder has met the main goal in a late-stage study.
3 Biotech Stocks That Could Benefit from the Patent Cliff
07:06am, Monday, 27'th Apr 2026
Biotechnology stocks have seen a spike in merger and acquisition (M&A) activity. In March 2026 alone, there were 10 deals valued at approximately $31.5 billion.
Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial
07:01am, Monday, 27'th Apr 2026
Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition succeeded in a Phase 3 trial, a landmark for gene editing. The treatment uses Nobel Prize-winning Crispr technology
Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing
07:00am, Monday, 27'th Apr 2026
Phase 3 HAELO trial of lonvoguran ziclumeran (lonvo-z) met primary and all key secondary endpoints; favorable safety and tolerability data observed Single dose of lonvo-z freed most patients from bo
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
CAMBRIDGE, Mass., April 24, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Massachusetts Financial Services Co. MA Makes New $318,000 Investment in Intellia Therapeutics, Inc. $NTLA
04:26am, Sunday, 19'th Apr 2026
Massachusetts Financial Services Co. MA bought a new position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in the fourth quarter, according to the company in its most recent Form 13F filing with the
NTLA Stock Rises 20% in 3 Months: Here's What You Should Know
10:36am, Thursday, 16'th Apr 2026
Intellia stock climbs nearly 20% in three months as pipeline progress, lifted FDA holds, and late-stage study updates boost investor optimism.
2 Healthcare Stocks to Buy and 1 to Approach With Caution
05:00pm, Wednesday, 15'th Apr 2026
Zoetis has strong growth prospects and an attractive income program. BioNTech has a rich pipeline that could help jolt the stock as it makes clinical progress.
Colossal’s Ben Lamm Says Invasive Species Is a $5.4 Trillion Problem. Here’s His Solution
08:49am, Sunday, 12'th Apr 2026
Invasive species represent a $5.4 trillion global problem, with U.S. economic impact alone exceeding $500 billion annually. That's according to Ben Lamm, CEO of Colossal Biosciences. On episode 245 of
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 03'rd Apr 2026
CAMBRIDGE, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy?
05:28pm, Sunday, 08'th Mar 2026
Intellia Therapeutics is getting around a recent major regulatory setback. However, the stock still faces several potential issues.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 06'th Mar 2026
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Hold” by Brokerages
05:04am, Friday, 06'th Mar 2026
Shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA - Get Free Report) have received an average recommendation of "Hold" from the twenty-one analysts that are presently covering the stock, Marketbeat
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
09:07am, Tuesday, 03'rd Mar 2026
Ark Invest bought shares of MercadoLibre, Intellia Therapeutics, and Generate Biomedicines on Monday. MercadoLibre and Intellia Therapeutics are trading 33% and 45% below their 52-week highs, respecti
